Peptide Library

Human study PLS-00147

Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.primary · Revista espanola de enfermedades digestivas · 2018-01-01 · PMID 29271227 · DOI

Design and participants

Design
Cross-sectional study
Population
Patients with biopsy-assessed nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH)
Conditions
Nonalcoholic fatty liver, Nonalcoholic steatohepatitis
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Authors concluded that serum Tβ4 level can serve as a biomarker for diagnosing NASH and that it was negatively correlated with the liver's oxidation state.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta4 was measured as an endogenous serum biomarker, not administered, so the study gives no information on treatment effects.
    • abstract only: Only the PubMed abstract is available, and it is truncated around the p-value thresholds.
    • no control group: Cross-sectional comparison of NAFL and NASH patients. No thymosin beta4 was administered and there was no intervention or control arm.
    • small or imprecise: Only 45 patients were included (24 NAFL, 21 NASH), which limits precision.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 29271227, abstract (Conclusion sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 29271227, abstract (Objective and Methods sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 29271227, abstract (Methods sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 29271227, abstract (Methods sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 29271227, abstract (Methods sentences 1-3) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).